merged_drug-prices-medicare.txt
<question_number>1</question_number>
<answer>The $2,000 annual cap takes effect in 2025, one year before the new negotiated prices take effect in 2026</answer>

<question_number>2</question_number>
<answer>The Project 2025 playbook suggests repealing the negotiation program, potentially reducing the number of drugs negotiated</answer>

<question_number>3</question_number>
<answer>She cast the tiebreaking vote for the legislation and prioritized drug pricing reforms in her early campaign</answer>

<question_number>4</question_number>
<answer>N/A</answer>

<question_number>5</question_number>
<answer>$1,716</answer>

<question_number>6</question_number>
<answer>AbbVie and Johnson & Johnson (Imbruvica, $9,319)</answer>

<question_number>7</question_number>
<answer>Fiasp and NovoLog insulin products</answer>

<question_number>8</question_number>
<answer>71.6%</answer>

<question_number>9</question_number>
<answer>$19</answer>

<question_number>10</question_number>
<answer>$14,211</answer>